AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01712048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Submucosal Injection EMR
Description: Selective saline injection is applied to the layer of tissue underneath the polyp in order to create a safety cushion for resection. EMR is then performed with a standard snare.
Study NCT01712048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Underwater EMR
Description: Polypectomy is performed under full water emersion without the use of submucosal injection.
Study NCT02771860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: denosumab
Description: 60mg sc
Study NCT02771860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: denosumab
Description: 60mg sc
Study NCT02771860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical syringe
Study NCT02771860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium/Vit D supplementation
Description: Daily dosage Calcium 1000mg / Vit D 880 IU
Study NCT02771860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium/Vit D supplementation
Description: Daily dosage Calcium 1000mg / Vit D 880 IU
Study NCT01698268 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: TAP Block will be performed under ultrasound guidance via Sonosite device with an in-plane technique by the anesthesiologist.
Study NCT01698268 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local Infiltration
Description: Local infiltration of 0.5 cc/kg of 0.25% ropivacaine will be administered by the surgeon.
Study NCT01058291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6500
Description: Twelve weeks subcutaneous injection of 1 to 6 mg for the OFF state
Study NCT01058291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KW-6500 Placebo
Description: Twelve weeks subcutaneous injection for the OFF state
Study NCT00717795 — intervention group
Intervention type: BEHAVIORAL
Intervention: interview and physical activity
Description: For Arm 1 participants in the Physical Activity intervention condition will be assessed at baseline, and postintervention Follow-up (at 12 weeks post baseline).
Study NCT04247542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibezapolstat
Description: Investigational antibacterial agent
Study NCT04247542 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Active comparator
Study NCT03265964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Uridine
Description: Uridine is the active treatment in this clinical trial.
Study NCT03265964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill placebo is the inactive treatment comparator in this clinical trial.
Study NCT00717795 — intervention group
Intervention type: BEHAVIORAL
Intervention: interview and wait list
Description: Participants in the control condition (Arm 2)will be assessed at baseline and 12 weeks post baseline (Follow-up). At this time, the PA intervention will be offered at no cost to the participants in the control condition. If the waitlist participant chooses to complete the PA intervention after the 12 week waitlist period, program satisfaction will be assessed after study completion.
Study NCT01142505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: 4mg once daily granules for 10 days, given orally alone or with cold or warm food from the onset of a cold or wheezing attack.
Study NCT01142505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: 4mg once daily granules for 10 days, given orally alone or with cold or warm food from the onset of a cold or wheezing attack
Study NCT01730716 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Human spinal cord stem cell implantation
Description: Human spinal cord stem cell implantation in ALS patients.
Study NCT00152243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFT (uracil, tegafur)
Description: uracil-tegafur 360 mg per square meter per day orally 16 months
Study NCT00152243 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery alone
Description: Gastrectomy of tumour node metastasis(TNM) stage T2N1-2 gastric cancer.
Study NCT01269619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic back support
Description: A dynamic back support which provides pressure on the lumbar without pressure on the abdomen
Study NCT01269619 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Static back support
Description: A standard wrap-around sacro lumbar support
Study NCT03963921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HepaStem
Description: Heterologous human adult liver-derived progenitor cells
Study NCT02878096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-SK-1404
Description: In Part 1, each subject will receive a single PO dose of SK-1404 followed by an IV microtracer dose of \[14C\]-SK-1404.
Study NCT04736719 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Description: Apixaban dispensing claim is used as the exposure group
Study NCT04736719 — intervention group
Intervention type: DRUG
Intervention: Warfarin
Description: Warfarin dispensing claim is used as the reference group
Study NCT04056312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Memory retraining exercises
Description: Experimental group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
Study NCT04056312 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo controlled group memory exercise training
Description: Placebo group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
Study NCT02905357 — intervention group
Intervention type: DEVICE
Intervention: OCT
Description: Optical Coherence Tomography (OCT): Intracoronary imaging for amount and type of plaque as well as plaque rupture, ulceration, dissection and/or thrombosis.
Study NCT02905357 — intervention group
Intervention type: OTHER
Intervention: CMR
Description: Cardiac Magnetic Resonance Imaging (CMR): MRI of the heart to identify areas of infarction (damage) and/or edema (swelling).
Study NCT00921258 — intervention group
Intervention type: PROCEDURE
Intervention: prostate biopsy
Description: patient of control group will have :~* 1 prostate biopsy 3 months after diagnostic biopsy~* 1 prostate biopsy each year during 2 years~* 1 prostate biopsy each 2 years during 8 years
Study NCT00003190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00003190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV
Study NCT00003190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00003190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valspodar
Description: Given IV
Study NCT01137656 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acetylcholine and Blood
Description: The Acetylcholine solution will be infused intra-arterially at the dosage of 7.5 ug/min for 3 minutes, then 15ug/min for 3 minutes, then 30 ug/min for 3 minutes, after the infusion of normal saline. It will then be infused at 7.5ug/min for 3 minutes, followed by 15ug/min for 3 minutes, followed by 30 ug/min for 3 minutes after the infusion of autologous blood. This will be performed at 5-10 days and 35-42 days of blood storage time.
Study NCT03859648 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BONEBRIDGE
Description: Bone Conduction Implant
Study NCT03026283 — intervention group
Intervention type: DEVICE
Intervention: HeartFLow CT-FFR
Description: Patients receiving CCTA to diagnose stable chest pain or stable angina will receive CT-FFR to estimate rate of flow through the coronary arteries. The rate of flow will be compared to the rate found on Invasive FFR (the gold standard) if the subject receives invasive FFR.
Study NCT04076436 — intervention group
Intervention type: OTHER
Intervention: Drug: Intravenous fosfomycin
Description: Patients will be visited on days 1 (Day of the urine and blood culture taking), 2, 5, 7, 14, on the test of cure and on day 30.~Visit on day 1: First day of treatment. Basal data collection.~Visit on day 2: Blood collection to fosfomycin levels calculation.~Visits on days 5, 7, 14, on the test of cure (day 21): Clinical evolution data, Urocultures and Adverse effects.~Visit on day 30: Assess mortality
Study NCT04076436 — intervention group
Intervention type: OTHER
Intervention: Drug: Intravenous quinolone or beta-lactam
Description: Patients will be visited on days 1 (Day of the urine and blood culture taking), 5, 7, 14, on the test of cure and on day 30.~Visit on day 1: First day of treatment. Basal data collection.~Visits on days 5, 7, 14, on the test of cure (day 21): Clinical evolution data, Urocultures and Adverse effects.~Visit on day 30: Assess mortality
Study NCT03450408 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Method of placement of Foley bulb transcervical dilator
Description: This trial will assess two methods used to place a Foley bulb transcervical dilator.
Study NCT02840773 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peri-implanter sulcus fluid sampling
Description: PISF sampling was made twice
Study NCT02840773 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probing depth
Description: The change of probing depth between baseline and 12 month after prosthetic loading. Probing depth was measured with a plastic periodontal probe (mm)
Study NCT02840773 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crestal bone loss
Description: Crestal bone loss was measured on digital radiographs at baseline and after 1 year of prosthetic loading with a Java program me (Image-J 3.0 NIH, Bethesda, USA)
Study NCT02840773 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Presence of bleeding on probing
Description: The change bleeding on probing of between baseline and 12 month after prosthetic loading. Presence of bleeding on probing were performed at four sites of implants.
Study NCT02840773 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plaque index levels
Description: The change of plaque index level between baseline and 12 month after prosthetic loading. Presence of plaque index was performed at four sites of implants.
Study NCT05345366 — intervention group
Intervention type: OTHER
Intervention: non-applicable
Description: non-applicable
Study NCT02797145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin dose-adjusted
Description: Serum digoxin concentration : 0.5 to 0.9 nanogram/mL
Study NCT02797145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard dose
Description: the dose of digoxin will be determined at the physician's discretion using traditional dosing methods.
Study NCT00211432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension (15 mg)
Study NCT04307524 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic repair
Description: laparoscopic suture repair of cesarean scar niche
Study NCT03977584 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: [^18F]GTP1
Description: IV \[\^18F\]GTP1 will be administered up to three times. The first primary \[\^18F\]GTP1 tau PET scan will occur during any visit in the main protocol NCT01998841 (GN28352) from Week 130 to Week 224 and the second \[\^18F\]GTP1 tau PET scan from Week 248 to Week 260. The third and optional \[\^18F\]GTP1 tau PET scan will supplement the two primary scans.
Study NCT02375009 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty
Description: laser therapy to trabecular outflow pathway of the eye to lower intraocular pressure, delivered to 360 degrees of both eyes in a single session
Study NCT02877056 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopy
Description: Tissue samples taken from tumor and normal colorectal tissue during standard endoscopy before therapy.
Study NCT04232150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single-dose midazolam for sedation under spinal anesthesia.
Description: Induction of neuraxial anesthesia was done using 2.8cc of 0.5 % Heavy Bupivacaine and 20mcg fentanyl injected intrathecally for all patients. Supplemental oxygen was given via facemask with capnography monitoring. Group O received 0.025mg/kg midazolam at skin incision.
Study NCT04232150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double-dose midazolam for sedation under spinal anesthesia.
Description: Induction of neuraxial anesthesia was done using 2.8cc of 0.5 % Heavy Bupivacaine and 20mcg fentanyl injected intrathecally for all patients. Supplemental oxygen was given via facemask with capnography monitoring. Group M received 0.025mg/kg midazolam at skin incision and repeated 5 minutes before maximum stimulation.
Study NCT04232150 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia with no sedation.
Description: Induction of neuraxial anesthesia was done using 2.8cc of 0.5 % Heavy Bupivacaine and 20mcg fentanyl injected intrathecally for all patients. Supplemental oxygen was given via facemask with capnography monitoring.
Study NCT01430741 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)
Description: MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
Study NCT01430741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Getting To Outcomes
Description: GTO strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. GTO consists of a series of steps practitioners should follow in order to obtain positive results and then provides them with the guidance necessary to complete those steps with quality. According to GTO, carrying out an evidence based program includes a series of steps corresponding to three general areas: (1) planning - e.g., developing goals and performance targets, ensuring staff are trained in the evidence based program; (2) implementation - e.g., monitoring program activities, maintaining adherence to an evidence based program model, supervision; and (3) self-evaluation - e.g., tracking patient outcomes, using data to improve program operations.
Study NCT01430741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)
Description: MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
Study NCT00446732 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UroSshield
Description: Attachment of the UroShield device to the external part of the urinary catheter
Study NCT02720003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LTX DCB
Description: Treatment with a drug-coated balloon
Study NCT02603952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: 75 mg capsules orally BID from Day 1 to Day 5.
Study NCT02603952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oseltamivir
Description: 75 mg capsules orally BID from Day 1 to Day 5.
Study NCT02603952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8852
Description: MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered as a single IV infusion of 750 mg or 3000 mg on Day 1.
Study NCT02603952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is salt-water solution containing no active ingredients and administered as a single IV infusion on Day 1.
Study NCT04581538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention of parallel arm 2
Description: This intervention consists of the e-learning platform and the networking platform from the newly developed client-server software solution 24-h-QuAALity.~The e-learning platform offers concise evidence-based information on common clinical patterns, as well as examples of assistance, physical activity, nutrition and daily routine provided in the caregivers' mother tongues.The caregivers use the e-learning content according to the needs of their clients and their caring skills. After completing the e-learning courses they do a test to prove their knowledge.~The networking platform supports caregivers in communicating with other caregivers and relatives of the care receiver, with special consideration of language barriers. The caregivers use the networking platform primarily to get information or exchange it, if there are uncertainties in the care.
Study NCT04581538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention of parallel arm 3
Description: Intervention Description: This interventions represents the entire 24-h-QuAALity package consisting of the e-learning platform and networknig platform as specified under intervention 1 and the digital care documentation from the newly developed client-server software solution 24-h-QuAALity.~The digital care documentation aims at supporting caregivers in managing their daily tasks and facilitates exchange with other health professionals and palliative supply. The caregivers use the care documentation every day. They describe the caring and household activities they have done by their clients. The integrated emergency management empowers caregivers with lifesaving first aid skills and knowledge including an integrated voice communication and emergency call system. The emergency management system is used by caregivers when an emergency happens in which life-threatening diseases have to be managed.
Study NCT03763110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photo Activated Disinfection
Description: Photoactivated disinfection (PAD) is based on the interaction of a photosensitive antibacterial agent and a light source. It uses a nontoxic dye \[named photosensitizer PS\] and low-intensity visible light. In oxygen presentation, these combine to produce some cytotoxic species. The PS molecules attach to bacteria membrane
Study NCT03763110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic paste
Description: An antibiotic mixture composed of ciproﬂoxacin, metronidazole, and minocycline, known as triple antibiotic paste (TAP) or 3mix, has been the most widely used medicament, This goes back to the studies by Hoshino et al.1996
Study NCT04148222 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study
Study NCT01890382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: 30 g in total; twice a day (morning and evening)
Study NCT01890382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey plus creatine
Description: whey protein combined with creatine (30 g and 6.0 g in total; twice a day, respectively)
Study NCT01890382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: leucine supplementation
Description: 7.5 g/d in total; three times per day
Study NCT01890382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy protein
Description: 30 g in total; twice a day
Study NCT01890382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine
Description: 6.0 g in total; twice a day
Study NCT01890382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00846378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post conditioning
Description: after 30 seconds of re-established coronary flow following the therapeutic balloon dilatation and deflation, the same balloon will be re-inflated for 30 seconds and then again deflated for 30 seconds. This procedure of balloon inflation/deflation will be performed a total of 3 to 4 times.
Study NCT00846378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care for STEMI
Description: Usual care for treatment of TIMI 0 to TIMI 1 flow in occluded infarct related artery. Usual care includes reperfusion of the artery per operator discretion, i.e. primary stenting, thrombectomy, balloon inflation/deflation without timed intervals.
Study NCT03997448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg IV
Study NCT03997448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemiciclib 150mg PO
Study NCT04241159 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Young Plasma
Description: The experimental dosing will consist of once weekly administration of PF24 over a period of 8 consecutive weeks (8 total doses over 56 days). 250 mL single units of PF24 will be obtained from the South Texas Blood Bank and processed by the WFBH Blood Bank.~1 unit (250 mL) PF24, will be infused at 1 mL/kg/hr, once weekly for 8 consecutive weeks.
Study NCT04481971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Tablets
Study NCT04481971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lactose in capsules gelatin
Description: Tablets
Study NCT00857636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health literacy, health message
Description: The intervention will consist of three main components: (1) 2-hour in-class health literacy-focused education; (2) tailored telephone counseling; and (3) healthcare system navigation assistance tailored to the woman's specific barriers.